香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該 等內容而引致的任何損失承擔任何責任。 （於開曼群島註冊成立的有限公司） （股份代號：1952） Everest Medicines Limited 雲 頂 新 耀 有 限 公 司 自願公告 與麥科奧特簽訂協議 以於大中華區及其他亞洲市場商業化MT1013 本 公 告 由 雲 頂 新 耀 有 限 公 司（「 本 公 司 」， 連 同 其 附 屬 公 司 統 稱「 本 集 團 」）自 願 作 出。 本公司董事會（「董事會」）欣然宣佈，於2026年2月4日，本公司的間接全資附屬公 司雲頂新耀醫藥科技有限公司（「該附屬公司」）與陝西麥科奧特醫藥科技股份有限 公司（「麥科奧特」）訂立協議（「該協議」），據此麥科奧特已不可撤銷授予該附屬公 司於中國及亞太區（ 日本除外 ）的MT1013的獨家商業化授權，MT1013為全球首創 的雙 靶點受 體激動 劑多肽 ，可同 時靶向 鈣敏感 受體(Ca SR)及 成骨生 長肽(OGP) 受 體，開發主要用於治療繼發 ...

Core Viewpoint - The company has received a drug registration application acceptance notice for its product, Human Coagulation Factor IX, which is aimed at treating patients with Hemophilia B and is expected to enhance its product line and core competitiveness in the long term [1][4]. Group 1: Drug Information - The drug, Human Coagulation Factor IX, is an injectable formulation with a specification of 500 IU per bottle, intended for domestic production [1]. - It is indicated for patients with congenital Factor IX deficiency or those with low Factor IX levels due to other reasons, significantly improving their Factor IX levels to prevent and treat bleeding [2]. - The company aims to develop high-recovery rate blood-derived products, addressing the long-term clinical drug shortages for Hemophilia B patients [2]. Group 2: Approval Process - The company has received the acceptance notice for the drug registration, but it still requires approval from the National Medical Products Administration before it can be marketed [3]. - The company previously announced the receipt of a clinical trial approval notice for the same drug, indicating progress in the regulatory process [3]. Group 3: Impact on the Company - The receipt of the drug registration acceptance notice will not impact the company's current performance but is expected to enrich its product line and optimize product structure in the long term [4]. - This development is anticipated to enhance the comprehensive utilization rate of raw plasma and improve profitability, thereby strengthening the company's core competitiveness [4].

Trading Information Summary - On February 4, 2026, Jiet Bio (688026) closed at 18.41 yuan, up 0.99%, with a turnover rate of 1.33% and a trading volume of 18,700 shares, amounting to a total transaction value of 34.1688 million yuan [1] - The net inflow of main funds was 2.7775 million yuan, accounting for 8.13% of the total transaction value [2] - Retail investors experienced a net outflow of 2.9683 million yuan, representing 8.69% of the total transaction value [1] Company Announcement Summary - Jiet Bio is involved in a legal dispute with Shenzhen Hesheng Medical Technology Co., Ltd. regarding nine "Mold Procurement Contracts," with a total amount in dispute of 10,340,829.00 yuan [1] - The court ruled to terminate the contracts and rejected all claims from both parties, including Jiet Bio's other litigation requests and Hesheng Medical's counterclaims [2] - Jiet Bio has fully provided for bad debts related to the advance payment made to Hesheng Medical and plans to appeal the court's decision, with the impact on current and future profits yet to be determined [1]

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整性亦 不發表任何聲明，並明確表示概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任何損 失承擔任何責任。 Knature Biopharmaceutical Co., Ltd. 康 諾 生 物 製 藥 股 份 有 限 公 司 （「本公司」） （於中華人民共和國註冊成立的股份有限公司） 的申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會（「證監會」）的要求而刊 發，僅用作提供資訊予香港公眾人士。 本申請版本為草擬本，其內所載資訊並不完整，亦可能會作出重大變動。 閣下閱覽本文件，即代表 閣下知 悉、接納並向本公司、本公司的獨家保薦人、整體協調人、顧問及包銷團成員表示同意： 於本公司招股章程根據香港法例第32章《公司（清盤及雜項條文）條例》送呈香港公司註冊處處長登記前，不會向 香港公眾人士提出要約或邀請。 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據向香港公司註冊處處長登記的本公司招 股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 ...

Group 1 - Arcus Biosciences, Inc. (RCUS) shares have increased by 1.2% over the past four weeks, closing at $21.96, with a mean price target of $34.6 indicating a potential upside of 57.6% [1] - The average of 10 short-term price targets ranges from a low of $20.00 to a high of $52.00, with a standard deviation of $10.17, suggesting variability in analyst estimates [2] - Analysts are optimistic about RCUS's earnings prospects, as indicated by a positive trend in earnings estimate revisions, which historically correlates with stock price movements [4][11] Group 2 - The Zacks Consensus Estimate for the current year has increased by 1% over the last 30 days, with one estimate moving higher and no negative revisions [12] - RCUS holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates, indicating strong potential for upside [13] - While consensus price targets may not be reliable for predicting the extent of gains, they can provide guidance on the direction of price movement [14]

Core Viewpoint - Changchun High-tech, a leading company in the growth hormone industry, is experiencing a significant decline in net profit, with a forecasted drop of 91.48% to 94.19% for 2025 compared to the previous year [1] Group 1: Financial Performance - In the third quarter of 2025, Changchun High-tech reported a revenue of 9.807 billion yuan, a decrease of 5.6% year-on-year, and a net profit of 1.165 billion yuan, down 58.23% year-on-year [1] - The peak net profit for Changchun High-tech was 4.532 billion yuan in 2023, but it fell by 43% in 2024, indicating a continuing downward trend into 2025 [1] - The company anticipates a net profit of 150 million to 200 million yuan for 2025, marking a substantial decline from previous years [1] Group 2: Market and Product Dynamics - The sales of growth hormones are influenced by the number of adolescents and newborns, with increased competition also impacting performance [2] - Changchun High-tech's long-acting growth hormone and related products have been included in the new national medical insurance directory, effective January 1, 2026, with a price reduction of approximately 75% [2] - The company has adjusted its sales policies and pricing in response to industry policy changes and market conditions, which has contributed to reduced revenue and net profit [2] Group 3: Subsidiary Performance - Changchun High-tech's subsidiary, Baike Biological, is expected to report a net loss of 220 million to 280 million yuan for 2025, marking its first loss since going public, primarily due to intensified competition and decreased vaccination willingness [3] - The sales revenue of the shingles vaccine from Baike Biological has already seen a decline of 71.54% in 2024, continuing to be negatively affected in 2025 [4] - Factors affecting the shingles vaccine sales include public awareness of the disease, vaccination willingness, and increased market competition, leading to unsold inventory and returns [4]

Group 1 - The US ADP employment numbers for January fell short of expectations, indicating a continued slowdown in the labor market [1] - The major US stock indices showed mixed performance at the market open, with the Nasdaq down 0.16%, the S&P 500 up 0.08%, and the Dow Jones up 0.4% [1] Group 2 - AMD experienced a significant drop of nearly 12%, with expectations of a 5% decline in Q1 revenue to $9.8 billion, pending performance improvements in the second half of the year with the MI450 series [1] - Novo Nordisk's stock fell by 4.5%, as the company anticipates a 5%-13% decrease in sales and operating profit this year due to unprecedented pricing pressures [1] - Super Micro Computer's stock rose nearly 9%, as both Q2 performance and guidance exceeded expectations, driven by strong demand for AI data center equipment [1] - Synaptics saw a surge of over 51%, while Texas Instruments fell more than 2% following the announcement of a $7.5 billion acquisition of Synaptics [1]

Investment Rating - The report maintains a positive outlook on Innovent Biologics, indicating an "Outperform" rating for the stock, expecting a relative return exceeding the benchmark index over the next 12-18 months [18]. Core Insights - In FY25, Innovent achieved total product revenue of approximately CNY 11.9 billion, representing a year-on-year increase of 45%, marking the first time the company surpassed the CNY 10 billion milestone [5][6]. - The oncology product portfolio has expanded to 13 products, with core products like Tyvyt® (sintilimab injection) showing steady growth and new products contributing significantly to revenue [6][10]. - The chronic disease segment has seen significant commercialization results, with products such as mazdutide (GLP-1/GCG), tafolecimab (PCSK9), and teprotumumab (IGF-1R) driving revenue growth [7][9]. - In Q4 2025, total product revenue reached approximately CNY 3.3 billion, reflecting a 60% year-on-year increase, with six new drugs included in the National Reimbursement Drug List for 2026 [8][10]. - The company is progressing towards its revenue target of CNY 20 billion by 2027, with ongoing development in oncology, metabolism, autoimmune diseases, and ophthalmology [9]. Summary by Sections Financial Performance - Total product revenue for FY25 was approximately CNY 11.9 billion, a 45% increase year-on-year [5]. - Q4 2025 revenue was approximately CNY 3.3 billion, a 60% increase year-on-year [8]. Product Development - The oncology portfolio has expanded to 13 products, with core products maintaining steady growth [6]. - Significant commercialization in chronic diseases, with key products accelerating market uptake [7]. Market Position - The company is moving closer to its revenue target of CNY 20 billion by 2027, with a rich pipeline in various therapeutic areas [9].

Core Viewpoint - The announcement by Bohui Innovation regarding the introduction of strategic investor Tongying Group and the capital increase for its subsidiary Hebei Bohui highlights significant developments in the company's growth strategy and operational expansion [2]. Group 1: Strategic Investment - On August 5, 2019, the sixth board of directors of Bohui Innovation approved the introduction of Tongying Group as a strategic investor for its subsidiary Hebei Bohui [2]. - Tongying Group will invest by transferring 120 million shares (72% ownership) of Bohui Biological Pharmaceutical Co., Ltd. and providing cash of 446.75 million yuan for the capital increase [2]. Group 2: Operational Commitments - Tongying Group has committed to ensuring that five plasma collection stations in Luyuan, Yaoan, Shenzhou, Linxi, and Pingdu obtain necessary qualifications and pass inspections within 18 months after the share transfer [2]. - A supplementary agreement was signed in December 2021 to further solidify the investment terms and operational commitments [2]. Group 3: Recent Developments - On February 4, 2026, the eighth board of directors approved a supplementary agreement regarding the approval process for three plasma collection stations in Luyuan, Yaoan, and Pingdu [2]. - This supplementary agreement does not require approval from the company's shareholders [2].

Core Viewpoint - Chengdu Kanghua Biological Products Co., Ltd. announced a strategic decision to acquire 100% control of Nameixin Biotech through a phased capital increase and equity transfer, marking a significant integration of innovative biotech with a mature industrial platform [1][11]. Part 01: Nameixin Biotech - Nameixin, established in 2021, focuses on mRNA vaccine and drug development, emphasizing AI-driven innovation and addressing unmet clinical needs [12][13]. - The founding team has over 20 years of experience in virology, immunology, and vaccine development, with key members having held significant positions in top research institutions and multinational corporations [2][13]. - Nameixin has developed a comprehensive technology platform covering target screening, antigen design, mRNA sequence optimization, LNP delivery system development, and lyophilized formulation processes [13][15]. - The company has applied for 14 invention patents, including one PCT international patent, and has obtained six software copyright registrations [15]. - Nameixin's core product, the RSV mRNA vaccine NR222, received clinical trial approval in December 2024, becoming the first lyophilized mRNA vaccine to enter clinical trials in China [6][17]. Part 02: Kanghua Biological - Founded in 2004, Kanghua is the first company in China to produce and sell human diploid cell rabies vaccines, recognized as a "gold standard" by WHO [7][18]. - The company is transitioning from a single product focus to a multi-product strategy, planning to expand into mRNA, recombinant protein/VLP, polysaccharide protein conjugates, and novel adjuvants [18]. - Kanghua's acquisition by Shanghai Biomedical Investment Fund marks a new development phase, with a 21.91% stake acquired [18][20]. - The company has established a strong academic promotion system covering thousands of disease control centers across China, enhancing its brand influence [19]. Part 03: Collaborative mRNA Vaccine Development - The collaboration between Nameixin and Kanghua aims to create a closed loop in mRNA vaccine development, production, and market access [19]. - Kanghua's existing production and R&D facilities, including a 14,000 square meter lab in Wenjiang, provide a solid foundation for large-scale GMP production and quality management [19]. - The partnership will leverage Shanghai's strategic position to enhance collaboration with universities, research institutions, and clinical organizations, facilitating international research pathways [20][21]. - The integration of Nameixin's innovative technology with Kanghua's industrial capabilities is expected to address long-standing clinical needs and enhance the accessibility of mRNA vaccines [21].